Table 2.

Predictors of Quantitative Interstitial Abnormality Progression Between Visits 1 and 2

Predictor	COPDGene		PLuSS
	Effect,a Mean (95% CI)	P Value	Effect,a Mean (95% CI)	P Value
Age at enrollment (per year of age)	0.01 (0.01-0.02)	< .001	0.02 (0.01-0.02)	< .001
Female sex	0.07 (0.02-0.12)	.003	0.14 (0.02-0.26)	.025
Current smoker (vs former)	0.10 (0.06-0.15)	< .001	0.001 (–0.10 to 0.10)	.98
MUC5B minor allele (per copy)	0.12 (0.07-0.16)	< .001	…b	…b

Adjusted for age; sex; baseline: quantitative interstitial abnormalities, emphysema, airway wall thickness (COPDGene only), smoking status, pack-years, BMI, and FEV₁; and change in: emphysema, smoking status (COPDGene only), BMI, FEV₁, and scanner manufacturer. Analyses of age at enrollment, female sex, and current smoking status were additionally adjusted for self-reported race. Analysis of MUC5B was adjusted for principal components of genetic ancestry. COPDGene = Genetic Epidemiology of COPD; PLuSS = Pittsburgh Lung Screening Study.

^aEffect expressed as the association between the noted exposure and the annual rate of change (percent per year) in quantitative interstitial abnormalities.

^bInformation unavailable.